Topical Beta-Blocker Formulation for Infantile Hemangioma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infantile hemangiomas, such as oral beta blockers, pose significant side effects due to systemic drug exposure, and there are no topical agents approved for this indication, necessitating a more effective and safer treatment method.
Innovation Solution
Topical or transdermal delivery of beta blockers with short half-lives, such as Esmolol and Landiolol, combined with skin permeation enhancers and esterase inhibitors, to minimize systemic absorption and maximize local efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral beta blockers like propranolol are used to treat Infantile Hemangiomas, then treatment effectiveness is achieved, but systemic absorption causes significant side effects
Solution Approach 1:
The patent extracts the harmful systemic circulation aspect from the treatment by using topical application that targets only the hemangioma lesion. The active ingredient is applied locally and remains confined to the treatment site, separating the therapeutic effect from systemic exposure and thereby eliminating cardiovascular and CNS side effects while maintaining treatment effectiveness.
Solution Approach 2:
The patent applies local quality by using topical formulations that deliver the beta blocker directly to the hemangioma tissue. The drug is concentrated at the application site with high local efficacy, while systemic absorption is minimized to negligible levels, creating a localized therapeutic effect without widespread systemic impact.
2Duration of action of moving object
If beta blockers with long half-lives are used, then sustained treatment effect is achieved, but systemic exposure increases and extends duration of side effects
Solution Approach 1:
The patent employs beta blockers with short half-lives (less than one hour) that are rapidly cleared from the body. These short-acting agents provide sufficient localized therapeutic effect during the application period but are quickly eliminated, preventing accumulation and minimizing systemic exposure duration, thereby reducing the window for potential side effects.
3Object-affected harmful factors
If topical beta blockers are used to avoid systemic absorption, then side effects are reduced, but treatment effectiveness may be compromised
Solution Approach 1:
The patent utilizes beta blockers with specific pharmacokinetic parameters - particularly short half-lives (less than one hour) and appropriate lipophilicity for skin penetration. These parameter optimizations ensure that the drug achieves sufficient concentration at the lesion site for effective treatment while being rapidly cleared systemically, thereby maintaining both efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Minimizes systemic side effects by ensuring high local drug concentration with minimal systemic exposure, reducing adverse reactions and potential long-term neurocognitive impacts.
Implementation Method 1
beta blockers which have high permeability through skin
Implementation Method 2
combined with skin permeation enhancers and esterase inhibitors
Data Source
AI summary
Transdermal delivery of beta blockers to treat Infantile Hemangiomas (IH) with reduced systemic circulation of the active drug and reduced or eliminated drug exposure to internal organs. In some embodiments, the beta blocker is esmolol. Pharmaceutical compositions according to the invention may be formulated lotions, creams, ointments, gels, foams, liquid dispersions, solutions, or aerosols.